Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
Dow
Baxter
AstraZeneca

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,117,844


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,117,844 protect, and when does it expire?

Patent 10,117,844 protects EPANOVA and is included in one NDA.

This patent has fifty-four patent family members in thirty-five countries.

Summary for Patent: 10,117,844
Title:DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Inventor(s): Maines; Timothy J. (Potomac, MD), Machielse; Bernardus N. (North Potomac, MD), Mehta; Bharat M. (Mendham, NJ), Wisler; Gerald L. (Windermere, FL), Davidson; Michael H. (Highland Park, IL), Wood; Peter Ralph (Glen View, GB)
Assignee: Omthera Pharmaceuticals, Inc. (Princeton, NJ) Chrysalis Pharma AG (CH)
Application Number:14/699,556
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,117,844

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,117,844

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013201793 ⤷  Free Forever Trial
Brazil 112014016788 ⤷  Free Forever Trial
Canada 2860512 ⤷  Free Forever Trial
Chile 2014001803 ⤷  Free Forever Trial
China 104321055 ⤷  Free Forever Trial
China 107050457 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Medtronic
Boehringer Ingelheim
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.